5577-20-8Relevant articles and documents
A Fluorescent Probe for Stimulated Emission Depletion Super-Resolution Imaging of Vicinal-Dithiol-Proteins on Mitochondrial Membrane
Yang, Zhigang,Kang, Dong Hoon,Lee, Hoyeon,Shin, Jinwoo,Yan, Wei,Rathore, Bhowmira,Kim, Hye-Ri,Kim, Seo Jin,Singh, Hardev,Liu, Liwei,Qu, Junle,Kang, Chulhun,Kim, Jong Seung
, p. 1446 - 1453 (2018)
Realizing the significant roles of vicinal-dithiol proteins (VDPs) in maintaining the cellular redox homeostasis and their implication in many diseases, we synthesized a smart arsenate based fluorescent probe 1 which can preferentially target the mitochon
Arsenic trioxide targets Hsp60, triggering degradation of p53 and survivin
Cheung, Yam Fung,Hu, Xuqiao,Ip, Tiffany Ka-Yan,Koohi-Moghadam, Mohamad,Li, Hongyan,Naranmandura, Hua,Ng, Kwan-Ming,Sun, Hongzhe,Tritton, Daniel N.,Tse, Eric Wai-Choi,Wang, Haibo,Wang, Runming,Wang, Yi,Wang, Yuchuan,Yang, Xinming
, p. 10893 - 10900 (2021/08/24)
The mechanisms of action of arsenic trioxide (ATO), a clinically used drug for the treatment of acute promyelocytic leukemia (APL), have been actively studied mainly through characterization of individual putative protein targets. There appear to be no studies at a system level. Herein, we integrate metalloproteomics through a newly developed organoarsenic probe, As-AC (C20H17AsN4O3S2) with quantitative proteomics, allowing 37 arsenic binding and 250 arsenic regulated proteins to be identified in NB4, a human APL cell line. Bioinformatics analysis reveals that ATO disrupts multiple physiological processes, in particular, chaperone-related protein folding and cellular response to stress. Furthermore, we discover heat shock protein 60 (Hsp60) as a vital target of ATO. Through biophysical and cell-based assays, we demonstrate that ATO binds to Hsp60, leading to abolishment of Hsp60 refolding capability. Significantly, the binding of ATO to Hsp60 disrupts the formation of Hsp60-p53 and Hsp60-survivin complexes, resulting in degradation of p53 and survivin. This study provides significant insights into the mechanism of action of ATO at a systemic perspective, and serves as guidance for the rational design of metal-based anticancer drugs. This journal is
Thiourea-containing arsenic sugar with anti-tumor activity and preparation method and application thereof
-
, (2020/04/02)
The invention relates to the field of arsenic sugar, and in particular relates to thiourea-containing arsenic sugar with anti-tumor activity and a preparation method and application thereof. The thiourea-containing arsenic sugar is composed of two compounds: 1-(N-(4'-(1'', 3'', 2''-dithiaarsenic pentane-2-yl) phenyl)-thiourea)-2, 3, 4, 6-O-acetyl-beta-D-glucose and 1-(N-(4'-(1'', 3 '', 2''-dithiaarsenic hexane-2-yl) phenyl)-thiourea)-2, 3, 4, 6-O-acetyl-beta-D-glucose. The thiourea-containing arsenic sugar provided by the invention has the advantages of simple reaction operation and high yield. The thiourea-containing arsenic sugar with a specific three-dimensional configuration can be obtained, and the thiourea-containing arsenic sugar has good anti-tumor activity.